Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $10.9 million.

  • Caribou Biosciences' Cash from Investing Activities fell 5908.53% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 15558.76%. This contributed to the annual value of $86.6 million for FY2024, which is 22702.14% up from last year.
  • Latest data reveals that Caribou Biosciences reported Cash from Investing Activities of $10.9 million as of Q3 2025, which was down 5908.53% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Cash from Investing Activities ranged from a high of $49.4 million in Q1 2025 and a low of -$174.0 million during Q4 2021
  • Its 5-year average for Cash from Investing Activities is -$8.8 million, with a median of $1.2 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 32765909.09% in 2022, then soared by 17918.13% in 2023.
  • Caribou Biosciences' Cash from Investing Activities (Quarter) stood at -$174.0 million in 2021, then soared by 100.67% to $1.2 million in 2022, then crashed by 2790.09% to -$31.5 million in 2023, then soared by 150.61% to $15.9 million in 2024, then crashed by 31.88% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $24.0 million for Q2 2025, and $49.4 million during Q1 2025.